MCSA-5872 OMB No.: 2126-0081 Expiration Date: 01/31/2027

## U.S. Department of Transportation Federal Motor Carrier Safety Administration

A Federal agency may not conduct or sponsor, and a person is not required to respond to, nor shall a person be subject to a penalty for failure to comply with a collection of information subject to the requirements of the Paperwork Reduction Act unless that collection of information displays a current valid OMB Control Number. The OMB Control Number for this information collection is 2126-0081. Public reporting for this collection of information is estimated to be approximately 8 minutes per response, including the time for reviewing instructions, gathering the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: Information Collection Clearance Officer, Federal Motor Carrier Safety Administration, MC-RRA, 1200 New Jersey Avenue SE, Washington, D.C. 20590.

## NON-INSULIN-TREATED DIABETES MELLITUS ASSESSMENT FORM

DOB:
rmine whether the individual meets the physical qualification standards of operate a commercial motor vehicle in interstate commerce. During the ual has a diagnosis of non-insulin-treated diabetes mellitus. Although diabetes mellitus, this information will be used by the certifying emplications and/or target organ damage and to determine whether the the individual to operate a commercial motor vehicle safely. The final this form is physically qualified to drive a commercial motor vehicle
review and complete this form, and return it to me via the individual, er specified below.
Signature of Certified Medical Examiner
Email
Fax Number
City, State, Zip Code

\*\*This document contains sensitive information and is for official use only. Improper handling of this information could negatively affect individuals. Handle and secure this information appropriately to prevent inadvertent disclosure by keeping the documents under the control of authorized persons. Properly dispose of this document when no longer required.\*\*

MCSA-5872 OMB No.: 2126-0081
Expiration Date: 01/31/2027

	5. Department of Transportation Ieral Motor Carrier Safety Administration			Expiration Date: 01/31/2027
Dri	iver Name:			
No	on-Insulin-Treated Diabetes Mellitus D	iagnosis		
1.	Date of diabetes mellitus diagnosis:			
2.	Medications - List all diabetes-related n (attach additional pages if necessary)	nedications, dosage, and o	date treatment initiated	
	Medication:	Dosage:	Date started: _	
	Medication:	Dosage:	Date started: _	
	Medication:	Dosage:	Date started: _	
Bl	ood Glucose Self-Monitoring			
3.	How many times per day is the individu	al testing blood glucose l	evels?	
4.	Is the individual compliant with glucose monitoring based on the individualized diabetes treatment plan?  Yes No			
Di	abetes Management and Control			
5.	Has the individual been on a stable individualized diabetes treatment plan with good glucose control?  Yes No  If no, explain why not (attach additional pages if necessary):			
6.	6. Has the individual experienced any recent severe hypoglycemic episodes (e.g., episodes requiring the assistance of others or resulting in loss of consciousness, seizure, or coma)?  [Yes  No  If yes, provide date(s) of occurrence and associated details (attach additional pages if necessary):			
7.	Has the individual experienced any rece hyperglycemic hyperosmolar syndrome.  Yes No If yes, provide date(s) of occurrence and	)?		

<sup>2</sup> 

<sup>\*\*</sup>This document contains sensitive information and is for official use only. Improper handling of this information could negatively affect individuals. Handle and secure this information appropriately to prevent inadvertent disclosure by keeping the documents under the control of authorized persons. Properly dispose of this document when no longer required.\*\*

MCSA-5872 OMB No.: 2126-0081 Expiration Date: 01/31/2027 U.S. Department of Transportation

Fed	ederal Motor Carrier Safety Administration		
Dri	ver Name:		
Не	emoglobin A1c (HbA1c) Measurements		
3.	Has the individual had HbA1c measured intermittently over the last 12 months?		
	☐ Yes ☐ No		
	If yes, attach the most recent result.		
)i	abetes Complications		
9.	Does the individual have signs of diabetes complications or target organ damage?		
	a. Renal disease/renal insufficiency (e.g., diabetic nephropathy, proteinuria, nephrotic syndrome)?		
	Yes No		
If yes, provide the date of diagnosis, current treatment, and whether the condition is stable:			
	b. Cardiovascular disease (e.g., coronary artery disease, hypertension, transient ischemic attack, stroke, peripheral vascular disease)?		
	☐ Yes ☐ No		
	If yes, provide the date of diagnosis, current treatment, and whether the condition is stable:		
	Novelogical discoss/outonomic novemethy (a a conditional and the discossional acquire and 2)		
	c. Neurological disease/autonomic neuropathy (e.g., cardiovascular, gastrointestinal, genitourinary)?  Yes No		
	If yes, provide the date of diagnosis, current treatment, and whether the condition is stable:		
	If yes, provide the date of diagnosis, earrent treatment, and whether the condition is stable.		
	d. Peripheral neuropathy (e.g., sensory loss, decreased sensation, loss of vibratory sense, loss of position sense)?		
	Yes No		
	If yes, provide the date of diagnosis, current treatment, and whether the condition is stable:		
	e. Lower limb (e.g., foot ulcers, amputated toes/foot, infection, gangrene)?		
	Yes No		
	If yes, provide the date of diagnosis, current treatment, and whether the condition is stable:		

<sup>\*\*</sup>This document contains sensitive information and is for official use only. Improper handling of this information could negatively affect individuals. Handle and secure this information appropriately to prevent inadvertent disclosure by keeping the documents under the control of authorized persons. Properly dispose of this document when no longer required.\*\*

OMB No.: 2126-0081 Expiration Date: 01/31/2027

arrent treatment, and whether the condition is stable:
ere non-proliferative diabetic retinopathy or proliferative diabetic
ndividual.
Signature of Treating Healthcare Provider
 Date
 Email
City, State, Zip Code

<sup>4</sup> 

<sup>\*\*</sup>This document contains sensitive information and is for official use only. Improper handling of this information could negatively affect individuals. Handle and secure this information appropriately to prevent inadvertent disclosure by keeping the documents under the control of authorized persons. Properly dispose of this document when no longer required.\*\*